Characterizing ectopic pregnancies that rupture despite treatment with methotrexate

Area of Science:

• Reproductive Endocrinology
• Gynecologic Surgery
• Pharmacologic Treatment of Ectopic Pregnancy

Background:

• Ectopic pregnancy remains a leading cause of early pregnancy mortality.
• Methotrexate (MTX) is a common medical treatment for ectopic pregnancy.
• Tubal rupture is a serious complication requiring surgical intervention.

Purpose of the Study:

• To identify predictive factors for tubal rupture in ectopic pregnancies treated with methotrexate (MTX).
• To evaluate the role of human chorionic gonadotropin (hCG) dynamics in MTX-treated ectopic pregnancies.

Main Methods:

• Retrospective case-control analysis of 81 women with ectopic pregnancy treated with MTX.
• Analysis of serial human chorionic gonadotropin (hCG) values before and after MTX administration.
• Comparison of hCG incremental rates and implantation site between patients with tubal rupture and those with resolution.

Main Results:

• An elevated hCG incremental rate before and after MTX treatment independently predicted tubal rupture.
• An hCG increase of at least 66% over 48 hours prior to diagnosis was a significant predictor.
• Rising hCG levels post-methotrexate treatment also indicated increased rupture risk.
• A higher proportion of ruptures occurred in the tubal isthmus (47%).

Conclusions:

• The rate of hCG increase before and after MTX is an independent risk factor for tubal rupture.
• Close monitoring of hCG levels, particularly rapid increases, may necessitate earlier surgical intervention.
• Implantation site may be an uncharacterized risk factor for tubal rupture.